Eosinophilic granulomatosis with polyangiitis: EGPA symptoms, asthma, ANCA and treatment

Eosinophilic granulomatosis with polyangiitis (EGPA), formerly called Churg–Strauss syndrome, combines eosinophilic inflammation, often asthma/sinus disease, and possible small-vessel vasculitis in several organs. Disease overview. Confidence is high that new heart, nerve or other organ abnormalities require prompt assessment. Many patients are ANCA-negative; neither a negative antibody result nor improvement in asthma proves that every organ is safe.

Table of contents

• Evidence summary
• What EGPA is: asthma, eosinophilia and older names
• How it works and how diagnosis is established
• Treatment: organ-threatening and respiratory disease
• Supplement and lifestyle evidence
• What works and what remains uncertain
• Risks, side effects and urgent warning signs
• Interactions and situations needing extra care
• Who needs assessment
• Clinician-led treatment and practical follow-up
• Animal and in vitro evidence
• Funding and source roles
• Frequently asked questions
• Sources and funding notes

Evidence summary

The practical verdict is to establish the clinical phenotype and organ threat before judging therapy. NHLBI vessel-disease context. EGPA requires coordinated respiratory and systemic care, with medication toxicity considered alongside the disease.

No trial percentage predicts an individual’s remission or steroid-free future. A clinical framework can still explain the questions that a treating specialist must resolve.

What EGPA is: asthma, eosinophilia and older names

Eosinophils are white blood cells involved in immune responses. EGPA can involve eosinophil-rich tissue inflammation and vasculitis. The 2023 European original describes overlapping clinical patterns; proposed allergic, eosinophilic and vasculitic phases need not occur in a fixed sequence.

The NHS overview describes asthma/allergic symptoms alongside possible weakness, numbness, kidney disease and heart-muscle injury. EGPA is not simply a new name for severe asthma. Conversely, having asthma does not mean a person will develop systemic vasculitis.

The Vasculitis Foundation written guide includes skin, bowel, heart and nerve symptoms. Their distribution varies. Painful or weak nerves, chest symptoms or blood in stools need an explanation beyond a general label of allergy. Retain older Churg–Strauss reports because their investigations may remain clinically useful.

How it works and how diagnosis is established

The initiating cause remains incompletely understood. NHLBI cause context. Immune mechanisms, possible exposures and medicine associations across vasculitis are not proof that one vaccine, food or treatment caused an individual case.

The European guideline distinguishes research classification criteria from diagnostic rules. It also explains why negative ANCA does not exclude EGPA. Diagnosis requires the clinical pattern and investigation of alternatives; a points calculator is not a substitute.

The NHLBI diagnostic overview describes combining blood/urine studies, imaging and selected biopsy. Ask what each test will establish and what its limits are. A biopsy can be useful, but the clinical team determines feasibility and whether waiting would risk harm.

Hypereosinophilic syndromes, infection and other causes of eosinophilia can require different management. The 2025 BSR original recommends specialist multidisciplinary assessment. A team may need respiratory, rheumatology, kidney, heart, neurology or hematology expertise according to the findings.

Treatment: organ-threatening and respiratory disease

The ACR/VF original distinguishes severe EGPA treated with glucocorticoids plus cyclophosphamide or rituximab from selected nonsevere disease. It also supports cardiac assessment at diagnosis. These are attributed, largely conditional recommendations rather than independently cleared product comparisons.

The newer BSR 2025 recommendations describe anti-IL-5/IL-5-receptor options for non-life/non-organ-threatening disease and different immune strategies for threatened organs. Guidance, access and licensed age/indications vary. The exact drug plan must fit the presentation, not just an antibody result.

The FDA approval record confirms adult-EGPA benralizumab approval in September 2024. Approval identity is a regulatory fact, distinct from an independent ranking of its benefit. The May 2026 maker label says it is not treatment for acute asthma symptoms.

Respiratory care remains important. The NHS asthma guide describes inhaler technique and an action plan. Agree on the actual preventer/reliever plan with the respiratory team; this article supplies no inhaler dose or instruction to replace current treatment.

MIRRA was GSK/public-cofunded and MANDARA was AstraZeneca-funded. Both excluded recent organ/life-threatening disease. Their results do not automatically answer treatment of an acutely threatened heart or nerve, and their efficacy is excluded from this independent verdict.

Supplement and lifestyle evidence

No conflict-cleared human evidence in these sources establishes a supplement as treatment for EGPA or prevention of organ injury. A nutritional deficiency or a bone-health indication during steroid treatment is a separate assessment, not evidence of disease remission.

The NCCIH supplement guidance identifies interaction and safety gaps. An anti-inflammatory claim or lower laboratory marker is not demonstrated protection of the heart, nerves or kidneys. Report exact products before changing immune treatment or undergoing a procedure.

Activity and nutrition should reflect breathlessness, nerve weakness and current organ status. The NHLBI living-with guidance emphasizes continuing care. A practical plan can include rehabilitation, smoking avoidance and emotional support; it cannot document remission by itself.

What works and what remains uncertain

A useful assessment separates asthma/sinus control, systemic inflammatory activity, lasting damage and treatment toxicity. The French original recommendations discuss activity versus sequelae. A continuing nerve deficit may require rehabilitation without being proof of fresh vessel inflammation.

Follow-up should address several outcomes: symptom control, organ function, medication burden and daily functioning. A smaller eosinophil count is useful information but does not by itself establish every outcome. Ask how improvement will be judged in each involved organ and which new finding would change the plan.

The NHLBI treatment context describes organ-directed support alongside immune care. Treatment of a consequence and control of inflammation are related but distinct goals. A medicine change may reflect intolerance or clinical circumstances rather than universal superiority of another product.

Selected biologic trials do not settle all questions about induction, maintenance, long-term safety or rare presentations. Their definitions of remission differ from ordinary symptom descriptions. Manufacturer efficacy, brand testimonials and a claim that all patients can safely stop steroids are not adopted.

Risks, side effects and urgent warning signs

Severe breathing difficulty, chest pain with collapse, new stroke symptoms or major bleeding need emergency care. NHLBI complication context. In known EGPA, an acute illness may reflect vasculitis, infection, a treatment effect or another emergency; it should not wait for a routine specialist review.

An asthma attack can be life-threatening. Follow the agreed action plan and seek emergency help when symptoms are worsening or prescribed rescue treatment is not helping. NHS emergency guidance. A scheduled biologic injection does not replace acute rescue care.

Glucocorticoids can affect infection risk, bone, metabolism, mood and sleep. NHS prednisolone safety information. New fever or illness during immune treatment warrants prompt advice. The Liverpool cyclophosphamide leaflet also identifies blood-count, bladder and reproductive risks.

The Fasenra maker label warns of serious allergic reactions and helminth-infection considerations. Rapid swelling, breathing difficulty or collapse after treatment needs emergency care. Label-derived safety warnings are attributed despite Tier 4 provenance; no trial benefit percentage is adopted.

Interactions and situations needing extra care

Asthma can be worsened by some medicines, including aspirin/ibuprofen or beta blockers in susceptible people. NHS interaction context. Check an additional medicine with the team; do not stop an important cardiovascular prescription on your own because of a generic list.

The NHS prednisolone interaction guidance and methotrexate guidance require attention to pain medicines, antibiotics and supplements. Methotrexate with trimethoprim/co-trimoxazole can create serious risk. Infection prophylaxis must be coordinated with the exact immune regimen.

An EGPA diagnosis is not automatically an instruction to stop a leukotriene inhibitor. The ACR/VF recommendation distinguishes its respiratory role. Separately, the MHRA warning advises immediate medical attention for new mood, sleep or behavior changes with montelukast; the prescriber decides stopping if needed.

Review infection exposures, hepatitis history, pregnancy and fertility before immune treatment when feasible. Cyclophosphamide safety context. Current disease urgency and reproductive planning require a shared specialist decision; neither an online reassurance nor a blanket medicine ban is sufficient.

Who needs assessment

Asthma/sinus disease with unexplained eosinophilia and additional organ abnormalities warrants assessment. A person with longstanding asthma can still develop a separate systemic problem. The NHLBI organ-symptom context explains why skin, nerves, urine, chest and abdominal symptoms matter.

New weakness, loss of sensation, changing skin lesions, chest pain/palpitations or bowel bleeding deserves prompt review. EGPA symptom guidance. Timing and functional impact help the clinician distinguish a new process from an old consequence. Do not wait for every possible symptom to appear.

Known EGPA needs reassessment when symptoms recur or change, including during a taper or after an infection. Bring the prior tests and treatment timeline. State whether the concern is breathing, nerve function, gastrointestinal symptoms or another domain instead of relying solely on a remembered antibody result.

Clinician-led treatment and practical follow-up

Agree on who coordinates systemic and respiratory care and how to access urgent advice. A shared plan should state the involved organs, each medicine’s goal, monitoring and signs that trigger contact. Make it available when moving between specialist and community services.

Prolonged prednisolone should not be stopped suddenly; reductions need prescriber direction. NHS stopping safety. Starting a biologic also does not justify abruptly withdrawing an inhaled or systemic steroid. Illness or withdrawal symptoms can need separate review.

When methotrexate is prescribed for inflammation, administration is generally weekly, and a daily-dosing error needs urgent professional advice. NHS administration guidance. This statement supplies no personal dose and is not a recommendation that every person with EGPA should take it.

Discuss rehabilitation, fatigue, work limitations, sleep and emotional strain alongside organ monitoring. Keep a record of recent infections and medication reactions. A meaningful plan measures daily function and treatment tolerability as well as laboratory trends.

Animal and in vitro evidence

Cell and animal work can investigate eosinophils, immune pathways and vessel injury. A mechanism may justify further research without establishing that a supplement or experimental treatment benefits human EGPA. A biological target is not itself a clinical outcome.

The independent verdict requires relevant human safety and clinical outcomes with traced funding. Lower eosinophils in an assay or reduced lesions in a model cannot prove preserved heart function, nerve recovery or steroid-free remission. Sponsored efficacy and laboratory-to-human supplement extrapolation are excluded.

Funding and source roles

The original 2023 European and 2021 ACR/VF guidelines and 2025 BSR recommendations were read with printed financial statements. They carry mixed company author relationships; project funding is not stated in the inspected European original. BSR’s no-external-project-funding declaration is distinct from society support, author ties and corporate revenue routes. Both pivotal biologic trials have maker funding: MIRRA includes GSK and public NIAID, MANDARA AstraZeneca; both are Tier 4/D. The maker label is also Tier 4/D, used only for attributed warnings/indication context. Public education does not clear underlying trials. FDA/MHRA regulator finances include industry fees, disclosed separately.

Tier describes financial proximity; A–D describes credibility for the stated source role. Neither is a clinical certainty grade. Unknown finances remain unknown. Manufacturer- and sponsor-funded efficacy is excluded from the independent verdict; attributed clinical guidance is identified as guidance.

Frequently asked questions

Is Churg–Strauss syndrome the same as EGPA?
EGPA is the current name. Older reports can still contain important diagnostic and treatment evidence.

Can EGPA be ANCA-negative?
Yes. A negative antibody result does not exclude EGPA; the organ pattern and investigations matter.

Does asthma with high eosinophils prove EGPA?
No. Other eosinophilic and allergic disorders, infections and blood disorders must be considered.

Do biologic trials establish treatment of a threatened heart?
Not automatically. The pivotal trials excluded recent organ/life-threatening disease and had manufacturer funding; this guide excludes their efficacy claims.

Should I stop montelukast when diagnosed?
The diagnosis alone does not create an automatic stop rule. New mood, sleep or behavior changes require immediate medical advice under the MHRA warning.

Can a lower eosinophil count prove remission?
No single blood result establishes the status of every disease domain. Organ assessment, respiratory control and treatment harms need review.

Sources and funding notes

Original EESG 2023, ACR/VF 2021 and full BSR2025 texts were read, with methods and printed disclosures. The clinical recommendations are attributed, not an industry-free drug ranking. Original MIRRA text was retrieved from NCBI’s public article-text API and MANDARA from an official Belgian university original mirror, with funding/sponsor role and organ-threatening exclusions checked; separate full author forms remain unavailable. Current May2026 AstraZeneca label, FDA approval record, April2024 MHRA montelukast warning and MHRA FY25/26 funding review were opened. NHS asthma is reviewed April2025; older medicine-page dates are disclosed. No dose, score cutoff, trial response percentage or universal taper is supplied.

• Emmi et al.: original 2023 European EGPA guideline — Diagnostic limits and organ/respiratory distinctions, not cleared drug outcomes.
• ACR/VF: original 2021 AAV management guideline — Dated clinical framework; no cleared drug-effect percentages.
• BSR: original 2025 AAV management recommendations — 2025 treatment/service framework; avacopan advice requires 2026 regulatory correction.
• BSR: original sponsorship and partnership offers — Society income routes and headquarters; no proof of a named company funding the 2025 project.
• Terrier et al.: original French recommendations, 2020/2021 correction — HBV-associated PAN distinctions, assessment and safety context; sponsored outcomes excluded.
• Vasculitis Foundation: EGPA written guide — Organ symptoms and chronic follow-up; treatment-effect promises and videos not adopted.
• ACR: corporate support opportunities — Revenue model only.
• Vasculitis Foundation: audited FY 2024–25 accounts — Institutional funding model only.
• Vasculitis Foundation: awareness fundraising sponsors — Named commercial relationship only.
• NHS: vasculitis overview — Asthma/allergy, nerve, kidney and heart context; brief educational description not comprehensive current treatment guidance.
• NHS: asthma (April 2025) — Action plan, inhaler review, trigger/interaction and emergency context; no personal inhaler dose.
• NHLBI: vasculitis overview (May 2023) — Disease-family definition and vessel-size context; not cleared treatment trials.
• NHLBI: causes (May 2023) — Possible triggers and secondary causes; not an individual causal diagnosis.
• NHLBI: symptoms (May 2023) — Organ-specific manifestations and complications.
• NHLBI: diagnosis (May 2023) — Clinical, blood, urine, biopsy and imaging assessment; subtype-specific accuracy not assumed.
• NHLBI: treatment (May 2023) — Attributed general treatment context, not a comparative efficacy verdict.
• NHLBI: living with vasculitis (May 2023) — Follow-up, pregnancy planning and emergency complications; individual risks differ.
• NHLBI: budget and gift authority — Funding trace, not outcome evidence.
• NHS: prednisolone side effects — Infection, bone, metabolic and mood risks; medicine safety, not disease-specific efficacy.
• NHS: prednisolone use and stopping (February 2022) — Clinician-directed tapering and adrenal safety; stated review date has passed.
• NHS: prednisolone interactions (February 2022) — NSAID/aspirin and supplement cautions; dated general medicine context.
• NHS: methotrexate use (March 2023) — Weekly inflammatory-disease administration safety and monitoring; no personal dose.
• NHS: methotrexate interactions (March 2023) — Antibiotic, NSAID, supplement and vaccine review; stated review date has passed.
• NHS website: content and funding policy — Website funding and editorial safeguards only.
• NCCIH: using dietary supplements wisely — Safety and interaction limits, not proof of vasculitis efficacy.
• Liverpool University Hospitals: cyclophosphamide leaflet — Blood-count/bladder/infection/fertility safety; local instructions not a universal regimen.
• Liverpool University Hospitals: FY 2024/25 original accounts — Own provider funding route, not generic NHS branding.
• AstraZeneca: Fasenra US label, May 2026 — Attributed allergy, steroid-reduction, helminth and acute-asthma warnings only.
• FDA: adult-EGPA benralizumab approval identity — Confirms September 17, 2024 adult-EGPA approval; no outcome ranking.
• FDA: January 2026 funding overview — Regulator finance context only.
• MIRRA: original 2017 mepolizumab trial — Funding and eligibility limitations only; efficacy excluded.
• MANDARA: original 2024 benralizumab versus mepolizumab trial — Funding, trial population and comparison limits; no efficacy verdict.
• MHRA: April 2024 montelukast mental-health warning — New mood, sleep or behavior symptoms need immediate medical advice; no incidence estimate.
• MHRA: original FY 2025/26 report and accounts — Own regulator finance and headquarters trace only.

Last reviewed: October 4, 2026. Educational information; no personal diagnosis, medication dose or supplement regimen is supplied. Local approval, product labels and clinical circumstances may differ.